On Thursday, Lineage Cell Therapeutics (AMEX:LCTX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For
CARLSBAD, Calif., September 08, 2026--AlloSCOPE 5D Patent Release
Lineage Cell Therapeutics is rated Hold due to its reliance on out-licensing and a risk-adjusted fair value below the current share price. Click for more.
This is the newest page. Registered accounts read further back.